the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Dengue cases decline in ME35, four deaths reported

PUTRAJAYA: The number of dengue fever cases fell to 1,765 in the 35th Epidemiological Week (ME35) from Aug 25 to 31, compared to 1,980 cases the previous week.

Health director-general Datuk Dr Muhammad Radzi Abu Hassan said four deaths from dengue fever complications were also reported during the week.

He further said that the cumulative number of dengue fever cases reported up to ME35 was 96,572, compared to 80,201 cases for the same period in 2023.

“There were 88 deaths due to dengue fever complications compared with 57 fatalities in the same period last year,” he said in a statement today.

He also said that 64 hotspot localities were reported, down from 85 in the previous week.

ALSO READ: Dengue cases drop to 2,609 in week 30, four deaths reported

Of these, 45 were in Selangor, seven in the Federal Territories of Kuala Lumpur and Putrajaya, three each in Negeri Sembilan, Kelantan and Perak, and one each in Kedah, Sabah and Sarawak.

Dr Muhammad Radzi also said two chikungunya cases were reported, bringing the cumulative total to 70 cases.

As for Zika surveillance, he said 1,834 blood samples, eight urine samples and three cerebrospinal fluid samples were screened, and all results were negative.

He warned that the risk of dengue fever transmission typically rises during school and public holidays due to increased public movement.

Therefore, the Health Ministry is urging the community, including schools and contractors, to ensure that no containers are left to collect water around premises, which could serve as breeding grounds for Aedes mosquitoes before the second school term holidays.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings